Tim Beyers

So less than 50% is what I hear you saying.

Yeah.

Okay.

Karl, to beat, raise, or miss, and I'll put the dividend question to you this way, given that Novo Nordisk has been a little shakier, as Tom points out, is the dividend what you do to stabilize things amongst the investors, or is it like, let's conserve the cash and go again?

So we've got a miss and maybe a slight beat or meet.

Let's move on to Twist Bioscience, which is a company that we've looked at multiple times in Rule Breakers.

And Tom, I'm going to come to you because as we're recording, this is Monday morning, we got results.

They did provide some preliminary results, ticker TWST, on January 12th.

And now we have the real results.

So let me ask you, were you surprised?

Were you delighted?

What did you see?

Carl, let me just ask you very quickly on this, and then we'll move to our final segment.

Because this is a company that's in DNA research, is some of the chaos you talked about at FDA, does it apply to a company like Twist?

Are they caught in that web of chaos?

There you go.

All right.

That's Eli Lilly, ticker LLY, Novo Nordisk, ticker NBO, and Twist Bioscience, which reported this morning a good beaten raise.

Up next, we're going to preview tomorrow's show.

Thanks for tuning in.